84 results about "Lidocaine" patented technology

The invention belongs to the technical field of pharmaceutical preparations, and relates to a riptacaine cream as well as a preparation method and application thereof, and the preparation method of the riptacaine cream comprises the following steps: preparing carbomer gel, preparing an oil phase, preparing a water phase, primarily emulsifying, homogenizing and gelating, finely homogenizing and filling. According to the invention, polyoxyethylene (54) hydrogenated castor oil is innovatively used as an auxiliary material, triple functions of a co-melting solvent, an emulsifying agent and a stabilizing agent are realized at the same time, and any liquid grease, solvent or other surfactants do not need to be additionally added in the prescription. Through a unique'water-gel-oil 'composite structure design, oil drops are physically wrapped by a carbomer gel network and are positioned in network pores, so that the mechanical stability superior to that of a conventional emulsion is provided, and no layering is generated through high-speed centrifugal test verification. In conclusion, the invention develops the riptacaine preparation which has the advantages of few types of auxiliary materials, higher stability, quicker effect taking and capability of expanding a new dosage form and a new process.

The invention relates to the technical field of organ transplantation, and discloses organ preserving fluid, application and organ dynamic supercooling perfusion equipment. The organ preserving fluid is prepared from ribose, glucose, mannitol, lidocaine, adenosine, a high-molecular polymer, L-proline, trehalose, inorganic salt and organic salt. The high-molecular polymer comprises one of hydroxyethyl starch, polyethylene glycol and albumin. According to the organ preserving fluid disclosed by the invention, the freezing point of the perfusate is reduced through the micromolecular cryoprotectant, and meanwhile, the micromolecular cryoprotectant and the high-molecular polymer jointly inhibit formation and growth of ice crystals; the problem of liquid preservation at the temperature below zero is solved from the two dimensions of physics (reducing the freezing point and inhibiting ice crystals) and biology (maintaining cell viability), and feasibility is provided for long-time low-temperature transfer and transplantation of organs. The preserving fluid can be used for static preservation or perfusion preservation of various organs such as kidney, liver, heart, pancreas, lung, small intestine, skin and the like.

The utility model relates to an adjustable fixable perineum cold patch which comprises a metering type nursing pad and a medicine pad, the medicine pad is arranged at the position, corresponding to the perineum of a puerpera, of the metering type nursing pad, an adjustable fastening structure is arranged on the metering type nursing pad and used for firmly wearing the metering type nursing pad, and the medicine pad comprises a sanitary towel and an adhesive area. Liquid medicine is adsorbed on the front face of the sanitary towel, an adhesive area is arranged on the back face of the sanitary towel, the sanitary towel adheres to the metering type nursing pad through the adhesive area on the back face of the sanitary towel, and the liquid medicine is prepared from magnesium sulfate, normal saline and lidocaine. The cold compress effect is provided for the perineum wound of a puerpera through the frozen medicine pad, the pain of the perineum wound is relieved, in addition, the medicine pad has the medicine effect, medicine treatment can be provided for the perineum wound of the puerpera, subtraction of perineum edema is facilitated, the double effects of cold compress and edema removal are achieved through combination of the medicine pad and the medicine pad, and the pain of the puerpera can be further relieved; the recovery of the perineum is accelerated.

This invention discloses a bioactive glass and its preparation method, belonging to the field of bioactive glass technology. It aims to solve the problems of insufficient synergistic effect between antibacterial efficacy and bone-promoting activity in existing materials, as well as the inability to monitor in vivo degradation processes in real time. The bioactive glass comprises 44-48 parts silica; 22-27 parts calcium oxide; 22-27 parts sodium oxide; 5-7 parts phosphorus pentoxide; 2-4 parts europium zinc complex; 10-20 parts chitosan; 1-5 parts lidocaine; and 2-5 parts dilute acetic acid solution. The addition of the europium zinc complex promotes bone formation and enhances antibacterial activity, achieving a highly efficient synergy between anti-infection and tissue regeneration. Simultaneously, it provides optical tracking capabilities, allowing for non-destructive real-time monitoring of the material's degradation behavior and tissue integration in vivo via fluorescence imaging. This invention offers superior material performance and a simple preparation process, providing an innovative solution for the repair of infected bone defects.

The invention discloses a transdermal patch containing lidocaine, the transdermal patch comprises a polymer matrix layer, the polymer matrix layer comprises active ingredients lidocaine, an acrylic acid pressure-sensitive adhesive and a penetration enhancer, the weight content of the lidocaine is 21-33%, the weight content of the acrylic acid pressure-sensitive adhesive is 45-75%, the weight content of the penetration enhancer is 1-10%, and the weight content of the penetration enhancer is 1-10%. The weight content of the penetration enhancer is 3%-25%. The transdermal patch disclosed by the invention is simple in prescription and process, good in drug permeability and colloid application performance and high in stability, can be continuously used for a long time without causing skin irritation, and is suitable for treating peripheral nerve related pains, especially patients requiring long-term administration such as post-herpes zoster neuralgia.

The invention discloses a compound with a local anesthesia function as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The preparation method of the compound comprises the following steps: mixing and heating lidocaine and 2-bromoethanol to obtain a compound 1; the preparation method comprises the following steps: mixing dicarboxylic acid, N-hydroxysuccinimide, 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride and a solvent to obtain a mixed solution; mixing and dissolving a compound 1, alkali and a solvent, and then adding into the mixed solution; and then carrying out spin-drying, separation and purification to obtain the compound with the local anesthesia function. The medicine can be used as a local anesthetic or analgesic for long-acting nerve block or selective nerve block. The medicine can block nerve conduction, has biocompatibility and biodegradability, is expected to overcome the problems of short time efficiency of single-needle injection and the like, and improves the efficacy of the medicine.

The pain relieving and disinfecting nursing bag comprises a sealed bag, lidocaine cotton swabs and iodophor cotton swabs, storage cavities are formed in the sealed bag, access openings are formed in the outer wall of the sealed bag, the access openings are communicated with the storage cavities, the storage cavities correspond to the lidocaine cotton swabs and the iodophor cotton swabs one to one, and the lidocaine cotton swabs and the iodophor cotton swabs are arranged in the sealed bag. And the lidocaine cotton swab and the iodophor cotton swab are correspondingly placed in the accommodating cavity. According to the technical scheme, in the time interval process of waiting for medicine absorption, a patient can be examined for other items in advance, reasonable utilization of time is ensured, the steps of pasting and removing do not need to be conducted, operation is easy, venipuncture efficiency is not affected, and the method is also suitable for people sensitive to skin and meanwhile can be used for disinfection before venipuncture.

A stable liquid formulation for parenteral administration comprising lidocaine or a pharmaceutically acceptable salt thereof. The formulation comprises a low concentration of a sodium bicarbonate buffer in an aqueous solution having a pH of about 6.5 to about 7.2, sodium chloride, and optionally a pH adjusting agent. The liquid formulation is a stable formulation, supplied as a ready-to-use or finished product in a container or vial rich in carbon dioxide in the headspace.

The present invention relates to an injection composition for lipolysis, which is safe and effective, and more specifically, to an injection composition for lipolysis, which comprises: one or more compounds selected from the group consisting of hyaluronidase and pentoxifylline, and one or more compounds selected from the group consisting of hyaluronidase, pentoxifylline, pentoxifylline, pentoxifylline, pentoxifylline, pentoxifylline, pentoxifylline, pentoxifylline, pentoxifylline, pentoxifylline and pentoxifylline. 5 to 10% (v / v) of carnitine (Carnitine); and lidocaine (Lidocaine); and normal saline. As a composition having both safety and efficacy, the injection composition for lipolysis of the present invention has an excellent lipolysis effect, does not cause a yo-yo phenomenon over time, and thus has a characteristic of not causing side effects such as skin depression.

The invention discloses a cross-linked collagen implant containing lidocaine and a preparation method of the cross-linked collagen implant, and mainly relates to the technical field of collagen. Compared with the prior art, the cross-linked collagen implant containing lidocaine has the advantages that natural collagen is modified through chemical cross-linking, and the collagen implant which is safe, durable, low in glutaraldehyde residue and low in cytotoxicity and contains anesthetic components is prepared by combining freeze-drying and sterile production processes. The invention also provides an application method of the lidocaine-containing cross-linked collagen implant, which is characterized in that the lidocaine-containing cross-linked collagen implant is injected into a corium layer and is used for correcting moderate and severe nasolabial cleavage wrinkles.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to external nano-emulsion gel for treating male erectile dysfunction and application of the external nano-emulsion gel. The invention provides external nano-emulsion gel for treating male erectile dysfunction. The external nano-emulsion gel is prepared from lidocaine, carbomer, a surfactant, a cosolvent and water, the particle size of the nanoemulsion gel is 80 nm to 120 nm, and the pH value of the nanoemulsion gel is 6.0 to 7.0; according to the nano-emulsion gel, the solubility and the skin penetrability of a hydrophobic drug lidocaine are remarkably improved through a micro-emulsion / nano-emulsion technology, so that the transdermal absorption efficiency is improved by 3.3-4.0 times, and quick effect taking and long-acting effects are realized. The carbomer gel matrix also provides good smearing performance and retention performance, the smearing area is increased by 5-6 times compared with that of common gel, and the use experience is remarkably improved.

Provided are methods for treating trigeminal nerve pain in a subject in need thereof. The method may include administering to the subject by perineural injection of the trigeminal nerve a therapeutically effective amount of a composition comprising an alpha-2 adrenergic agonist, such as guanfacine. The composition may further comprise lidocaine.

The invention discloses an external antibacterial medicine composition as well as a preparation method and application thereof, and belongs to the technical field of antibacterial medicines. The external antibacterial pharmaceutical composition provided by the invention comprises a medicinal active component and a pharmaceutically acceptable carrier, wherein the medicinal active component comprises polymyxin B sulfate, trimethoprim sulfate and lidocaine; every 10 g of the antibacterial pharmaceutical composition for external use is prepared from the following components in parts by weight: 40000 to 60000 U of polymyxin B sulfate, 0.08 to 0.16 g of trimethoprim sulfate and 0.30 to 0.35 g of lidocaine. The pharmaceutical composition disclosed by the invention has broad-spectrum inhibition on multiple drug-resistant bacteria such as common gram-negative drug-resistant bacteria and acinetobacter baumannii on a wound surface, synchronously plays a synergistic role in relieving inflammatory response of the wound surface and relieving local pain, and remarkably improves the medication safety and the comprehensive treatment effect while ensuring excellent antibacterial activity.

Provided are methods for treating trigeminal nerve pain in a subject in need thereof. The method may include administering to the subject by perineural injection of the trigeminal nerve a therapeutically effective amount of a composition comprising an alpha-2 adrenergic agonist, such as guanfacine. The composition may further comprise lidocaine.

Described herein are aqueous pharmaceutical compositions comprising lidocaine, hyaluronic acid, and chondroitin sulfate (or a pharmaceutically acceptable salt of any one thereof) and water, as well as methods of making such aqueous pharmaceutical compositions and methods of treatment using them.

This invention discloses a method for preparing a hydrogel composite dressing for post-circumcision care, specifically implemented according to the following steps: Step 1, preparing an MXene nanosheet dispersion; Step 2, preparing a lidocaine-chitosan-gellan gel composite; Step 3, mixing the MXene dispersion from Step 1 with the lidocaine-chitosan-gellan gel composite from Step 2, and adding a menthol derivative to prepare a multifunctional hydrogel composite dressing. This invention also discloses the hydrogel composite dressing prepared by this method. This invention accelerates wound healing through the antibacterial, hemostatic, and epithelial cell regeneration-promoting effects of chitosan; through the photothermal conversion capability of MXene, local mild thermotherapy can be achieved under near-infrared light irradiation, promoting blood circulation and reducing edema, while MXene itself has good antibacterial properties.

This invention discloses a localized long-acting anesthetic sustained-release gel and its preparation method, belonging to the field of medical anesthetic sustained-release materials. In the preparation process, 100-300nm hollow SiO2 particles are first modified with PEG-PLA, and then emulsified using microfluidics to obtain a monodisperse suspension. Next, chitosan is dissolved, and anesthetic drugs such as lidocaine are added. The suspension is then added dropwise, and the carboxyl groups are activated using EDC-NHS, followed by a low-temperature reaction at 4°C to form a gel. This gel prolongs the drug effect through the "double drug barrier layer" of the modified hollow SiO2 particles, and its morphological stability is ensured within 24 hours by particle support. All materials are medical-grade biocompatible materials, and the microfluidic process solves particle aggregation, making it suitable for surface anesthesia.

The invention belongs to the technical field of pharmaceutical preparations, particularly discloses a colchicine and lidocaine eutectic mixture as well as a preparation method and application thereof, and aims to solve the problems that colchicine is poor in transdermal effect, large in gastrointestinal tract side effect after oral administration and insufficient to meet the anti-inflammatory and analgesic requirements of acute gout in time. According to the invention, colchicine and lidocaine are mixed according to a molar ratio of 0.1: 0.9-0.9: 0.1 to prepare a eutectic mixture with a melting point of 46.1-64.7 DEG C through a solvent-assisted grinding method, and the eutectic mixture is also prepared into an external pharmaceutical composition. The solubility and transdermal effect of the mixture are remarkably improved, colchicine and lidocaine can be locally and efficiently delivered to lesion joints, the complementary and synergistic effects of the two drugs on anti-inflammatory and analgesic mechanisms are fully played, meanwhile, the gastrointestinal toxic and side effects of oral administration are avoided, the safety is good, the skin tolerance is good, and the application prospect is wide. The medicine is suitable for treating acute gouty arthritis.

The application discloses a coating with lubricating, bacteriostatic and sustained-release characteristics and a preparation method and application thereof, and belongs to the technical field of medical materials, wherein the preparation method of the coating comprises the following steps: [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl) ammonium hydroxide, a crosslinking agent and an initiator are added into a solvent and mixed to obtain a solution A; polyvinylpyrrolidone and lithium chloride are added into the solution A and stirred to obtain a solution B; zinc oxide and a surfactant are added into the solution B and ultrasonic treatment is carried out to obtain a uniform suspension; lidocaine is added into eucalyptus oil and stirred to obtain a solution C; the solution C is added into the above suspension and ultrasonic treatment is carried out to obtain a Pickering emulsion; and the Pickering emulsion is subjected to ultraviolet light irradiation treatment to obtain the coating with the lubricating, bacteriostatic and sustained-release characteristics. When the coating is applied to the surface of a urinary catheter, the friction of the urinary catheter can be reduced, the urinary catheter is endowed with excellent bacteriostatic characteristics, and excellent drug sustained-release performance can be exhibited.

The present application belongs to the technical field of nanometer material preparation, and relates to a kind of nanometer medicine, including medicine carrier and active ingredient, medicine carrier adopts amphiphilic polymer, and active ingredient includes photosensitizer Ce6 and analgesic drug LC. The preparation method of the nanometer medicine is also disclosed, comprising the following steps: weighing Ce6, analgesic drug LC and amphiphilic polymer, dissolving in solvent to obtain a mixed solution; the mixed solution is stirred uniformly, and dialyzed in ultrapure water; the solution obtained by dialysis is constant volume, and filtered to obtain nanometer medicine. The nanometer medicine particle size morphology is regular, the particle size is uniform, has good stability within 7 days, can have good enrichment effect at tumor site, and has good photodynamic therapy effect. Lidocaine and photosensitizer reach the lesion site at the same time through intravenous injection, not only reduce the operation steps, but also target the lesion site, reduce the anxiety of patients because they feel that anesthesia will affect intelligence.

The invention belongs to the technical field of pharmaceutical preparations, and discloses a traditional Chinese medicine ointment with a tissue repair function and a preparation method of the traditional Chinese medicine ointment. The traditional Chinese medicine composition is prepared from, by weight, 3-10 parts of rhizoma coptidis, 3-10 parts of radix scutellariae, 3-10 parts of cortex phellodendri, 10-15 parts of radix angelicae sinensis, 5-10 parts of rhizoma bletillae, 5-10 parts of dragon's blood, 1-5 parts of pearl powder, 5-10 parts of radix arnebiae seu lithospermi, 5-10 parts of raw radix sanguisorbae, 1-5 parts of elephant hide, 10-15 parts of radix angelicae, 10-15 parts of radix salviae miltiorrhizae, 5-10 parts of radix paeoniae rubra, 5-10 parts of frankincense and 5-10 parts of myrrh. 5-10 parts by weight of safflower, 5-10 parts by weight of pseudo-ginseng and 10-15 parts by weight of honeysuckle; the composition further comprises lidocaine, an r-bFGF solution, multivitamins and an oily solvent. Vitamin C and vitamin E are added, so that the anti-oxidation effect of the formula can be further enhanced, collagen synthesis is promoted, and the immunity is enhanced. In combination with an r-bFGF solution, tissue repair and cell growth can be more effectively promoted.

The disclosure relates to pharmaceutical formulations comprising of lidocaine and halobetasol propionate, methods of making such formulations, and methods of using such formulations in the treatment of hemorrhoids.

The invention relates to a compound medicine for treating oral mucositis caused by luconobutuzumab and a preparation method of the compound medicine, and the compound medicine realizes the comprehensive curative effects of resisting inflammation, easing pain and promoting mucosal repair through combination of traditional Chinese medicines and western medicines and synergism of multi-ethnic medicines. The compound medicine is prepared from the following components in parts by weight: 0.1 to 0.5 part of recombinant human epidermal growth factor, 0.5 to 2.0 parts of lidocaine, 0.01 to 0.1 part of vitamin B12, 1.0 to 5.0 parts of astragalus polysaccharide, 0.5 to 3.0 parts of honeysuckle chlorogenic acid, 0.2 to 1.5 parts of glycyrrhizic acid, 0.1 to 1.0 part of crocin, 0.3 to 2.0 parts of saussurea involucrata flavone, 0.2 to 1.8 parts of paris polyphylla saponin and 0.4 to 2.5 parts of sculellaria barbata flavone. The compound provided by the invention is suitable for tumor patients receiving treatment of luconatobutuzumab, is especially suitable for patients suffering from I-III grade oral mucositis, can be used as a hospital preparation or new drug development, and has wide clinical application and market prospects.

This invention discloses a chitosan-based lidocaine formulation for intra-articular use and its preparation method. Belonging to the field of pharmaceutical formulation technology, the formulation is prepared from chitosan, carboxymethyl chitosan, lidocaine, chitosan-PNIPAM microspheres, sulfated trehalose, and excipients. The chitosan-PNIPAM used in this invention exhibits dual temperature and pH response. With temperature changes, PNIPAM possesses both hydrophobic contractile and hydrophilic swelling states, thereby controlling the lidocaine release rate. Simultaneously, when the pH decreases, chitosan repels PNIPAM, further disintegrating the microspheres to release the drug, thus achieving targeted analgesia. Sulfated trehalose, as a cartilage matrix synthesis promoter, can activate intracellular signaling pathways in chondrocytes, promoting the synthesis of type II collagen and proteoglycans. Simultaneously, the sulfate groups can form electrostatic complexes with the amino groups of chitosan, enhancing drug retention. The formulation of this invention can inhibit synovial cells, release cytokines, and synergistically with carboxymethyl chitosan, increase the inhibition rate of inflammatory factors by 40%-50%.

Methods are provided for insect control, including controlling fly maggot disease, in an animal by securing to the animal an elastic band impregnated or containing therein an insecticide, an insect repellant, lidocaine, or any combination thereof. The insect control may be dual mode control, and may be directed against existing or impending open wounds, including open wounds caused by castration, tagging, umbilical ligation, or chamfering of animals. Also provided are methods for castration, tail cutting, umbilical cord ligation, or chamfering of animals while insect control. Elastic bands for insect control and methods of making such elastic bands are also provided.

The present invention relates to compositions for use in the treatment of chronic, persistent or hyperinflammation and to methods for the treatment of chronic, persistent or hyperinflammatory conditions both of which involve prolonged or excessive inflammation, such as those experienced post an infection, particularly a viral infection, or following an autoimmune disease. An inclusion complex of lidocaine and cyclodextrins is demonstrated to provide therapeutic benefit, both causal and symptomatic, in Long COVID patients.

Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.

1.The name of the design product: packaging box (lincomycin lidocaine gel). 2.The use of the design product: for medicine packaging. 3.The design points of the design product: the combination of shape, pattern and color. 4.The picture or photo that best shows the design points: perspective view. 5.The design claimed contains color.

Provided is an injectable composition including a compound configured to form nanoparticles, an anesthetic agent, and a hyaluronic acid hydrogel. According to the present disclosure, the injectable composition is injected in a liquid formulation and gelated in the body to prevent rapid decomposition, sustained-release the anesthetic agent for a long period of time, and locally remain in the body for a long period of time. In addition, the injectable composition may provide a long-term, sustained pain relief effect through the stable sustained-release of lidocaine.

Lidocaine for use in the treatment of a chronic, persistent or hyperinflammatory condition, where the lidocaine is administered in a format and a dose that targets the lymphatic system, resulting in p